CD40–CEA Bispecific Polypeptides for Tumor-Localized Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies for cancers expressing carcinoembryonic antigen (CEA) are limited in efficacy and safety, with existing treatments often causing systemic toxicity due to non-specific activation of CD40-expressing cells outside tumor sites.
Innovation Solution
Development of bispecific polypeptides that specifically bind to CD40 and CEA, optimizing molecular formats to activate CD40-expressing cells only in tumor tissues, thereby minimizing systemic toxicity while enhancing localized anti-tumor immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing immunotherapies activate CD40-expressing cells systemically, then anti-tumor immune response is enhanced, but systemic toxicity increases
Solution Approach 1:
The bispecific polypeptide is designed to bind simultaneously to CD40 on immune cells and CEA on tumor cells, creating a localized interaction at the tumor site. This spatial restriction ensures that CD40 activation occurs only where CEA is present, converting systemic exposure into localized action and thereby enhancing anti-tumor efficacy while minimizing systemic toxicity.
Solution Approach 2:
The bisspecific polypeptide acts as an intermediary molecule that bridges CD40-expressing immune cells and CEA-expressing tumor cells. By requiring dual binding to function, the polypeptide mediates selective activation only at the tumor microenvironment, preventing unwanted systemic activation while maintaining therapeutic effectiveness.
2Measurement precision
If bisspecific polypeptides are designed for high specificity, then targeted activation is improved, but molecular format complexity increases
Solution Approach 1:
The bisspecific polypeptide integrates multiple binding specificities into a single molecular entity, with one arm binding CD40 and the other binding CEA. This multi-functional design achieves high targeting precision through dual recognition while using established antibody engineering platforms to manage structural complexity.
Solution Approach 2:
The polypeptide is constructed as a bispecific antibody with distinct binding domains for CD40 and CEA, allowing independent optimization of each binding interaction. This segmented architecture enables precise control over binding specificity while leveraging modular antibody formats to maintain structural manageability.
Data Source
AI summary
The present invention relates to novel bispecific polypeptides, such as antibodies, and their use in the treatment of cancers, particularly cancers expressing carcinoembryonic antigen (CEA).